United Therapeutics Corporation (NASDAQ:UTHR) Receives $509.50 Average Target Price from Analysts

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $509.50.

Several research firms recently weighed in on UTHR. UBS Group boosted their price objective on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. HC Wainwright lifted their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Wells Fargo & Company increased their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th.

United Therapeutics Trading Down 1.5%

NASDAQ UTHR opened at $483.23 on Friday. United Therapeutics has a 1 year low of $266.98 and a 1 year high of $519.99. The company has a fifty day simple moving average of $483.94 and a 200 day simple moving average of $403.09. The company has a market cap of $20.81 billion, a P/E ratio of 18.31, a P/E/G ratio of 2.51 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the previous year, the business earned $6.39 EPS. The business’s revenue was up 6.8% on a year-over-year basis. Equities research analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $417.50, for a total value of $9,393,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 582,014 shares of company stock worth $272,706,826. Insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the company. CWM LLC increased its position in United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after acquiring an additional 3,487 shares in the last quarter. AXQ Capital LP lifted its position in shares of United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after purchasing an additional 33,662 shares in the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of United Therapeutics in the third quarter valued at approximately $8,351,000. Finally, Merit Financial Group LLC raised its position in United Therapeutics by 56.3% in the 3rd quarter. Merit Financial Group LLC now owns 7,416 shares of the biotechnology company’s stock worth $3,109,000 after purchasing an additional 2,672 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.